/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2026-04-29 15:57:002026-04-29 15:57:00iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2026-03-17 14:58:122026-03-17 15:16:40iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2025-10-01 18:03:392025-10-02 02:20:56iECURE to Present OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at the European Society of Gene & Cell Therapy Annual Congress and the American Society of Human Genetics Annual Meeting
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2025-08-24 18:43:312025-08-24 18:50:58iECURE to Present Initial OTC-HOPE Clinical Trial Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at 6th International Symposium on UCDs and 15th International Congress of Inborn Errors of Metabolism
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2025-05-05 19:01:572025-05-06 12:38:54iECURE to Present Initial OTC-HOPE Clinical Data of ECUR-506 in Ornithine Transcarbamylase Deficiency at Upcoming Medical Meetings
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2025-03-21 09:06:012025-03-21 09:06:01iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2025-03-11 19:35:012025-03-11 19:35:01iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting
/wp-content/uploads/iEcure_logo.png00eallison/wp-content/uploads/iEcure_logo.pngeallison2025-01-08 19:08:512025-01-09 16:28:06iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png00David Anderson/wp-content/uploads/iEcure_logo.pngDavid Anderson2024-05-07 05:00:362024-05-07 08:06:38iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
